The histone acetyltransferase hMOF is frequently downregulated in primary breast carcinoma and medulloblastoma and constitutes a biomarker for clinical outcome in medulloblastoma (Q46866555)

From Wikidata

Jump to navigation Jump to search

The printable version is no longer supported and may have rendering errors. Please update your browser bookmarks and please use the default browser print function instead.

scientific article published in March 2008

Language	Label	Description	Also known as
English	The histone acetyltransferase hMOF is frequently downregulated in primary breast carcinoma and medulloblastoma and constitutes a biomarker for clinical outcome in medulloblastoma	scientific article published in March 2008

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

26 December 2017

http://europepmc.org/abstract/MED/18058815

The histone acetyltransferase hMOF is frequently downregulated in primary breast carcinoma and medulloblastoma and constitutes a biomarker for clinical outcome in medulloblastoma (English)

1 reference

Europe PubMed Central

PubMed publication ID

26 December 2017

http://europepmc.org/abstract/MED/18058815

medulloblastoma

0 references

1 reference

based on heuristic

inferred from title

breast carcinoma

1 reference

based on heuristic

inferred from title

3

1 reference

Europe PubMed Central

PubMed publication ID

26 December 2017

http://europepmc.org/abstract/MED/18058815

5

1 reference

Europe PubMed Central

PubMed publication ID

26 December 2017

http://europepmc.org/abstract/MED/18058815

8

1 reference

Europe PubMed Central

PubMed publication ID

26 December 2017

http://europepmc.org/abstract/MED/18058815

object named as

Stephen Rea

2

0 references

Stefan M. Pfister

object named as

Stefan Pfister

1

0 references

10

object named as

Peter Lichter

1 reference

Europe PubMed Central

PubMed publication ID

26 December 2017

http://europepmc.org/abstract/MED/18058815

6

object named as

Carina Ittrich

1 reference

Europe PubMed Central

PubMed publication ID

26 December 2017

http://europepmc.org/abstract/MED/18058815

author name string

Frank Mendrzyk

4

1 reference

Europe PubMed Central

PubMed publication ID

26 December 2017

http://europepmc.org/abstract/MED/18058815

Olaf Thuerigen

7

1 reference

Europe PubMed Central

PubMed publication ID

26 December 2017

http://europepmc.org/abstract/MED/18058815

Asifa Akhtar

9

1 reference

Europe PubMed Central

PubMed publication ID

26 December 2017

http://europepmc.org/abstract/MED/18058815

language of work or name

0 references

publication date

1 March 2008

1 reference

Europe PubMed Central

PubMed publication ID

26 December 2017

http://europepmc.org/abstract/MED/18058815

International Journal of Cancer

1 reference

Europe PubMed Central

PubMed publication ID

26 December 2017

http://europepmc.org/abstract/MED/18058815

122

1 reference

Europe PubMed Central

PubMed publication ID

26 December 2017

http://europepmc.org/abstract/MED/18058815

6

1 reference

Europe PubMed Central

PubMed publication ID

26 December 2017

http://europepmc.org/abstract/MED/18058815

1207-1213

1 reference

Europe PubMed Central

PubMed publication ID

26 December 2017

http://europepmc.org/abstract/MED/18058815

The language of covalent histone modifications

1 reference

https://api.crossref.org/works/10.1002%2FIJC.23283

21 January 2018

The diverse functions of histone acetyltransferase complexes.

1 reference

https://api.crossref.org/works/10.1002%2FIJC.23283

21 January 2018

Histone acetylation: a switch between repressive and permissive chromatin. Second in review series on chromatin dynamics.

1 reference

https://api.crossref.org/works/10.1002%2FIJC.23283

21 January 2018

Global histone modification patterns predict risk of prostate cancer recurrence

1 reference

https://api.crossref.org/works/10.1002%2FIJC.23283

21 January 2018

Histone deacetylases, transcriptional control, and cancer

1 reference

https://api.crossref.org/works/10.1002%2FIJC.23283

21 January 2018

Clinical development of histone deacetylase inhibitors as anticancer agents

1 reference

https://api.crossref.org/works/10.1002%2FIJC.23283

21 January 2018

Histone H4 acetylation in Drosophila. Frequency of acetylation at different sites defined by immunolabelling with site-specific antibodies

1 reference

https://api.crossref.org/works/10.1002%2FIJC.23283

21 January 2018

Loss of acetylation at Lys16 and trimethylation at Lys20 of histone H4 is a common hallmark of human cancer

1 reference

https://api.crossref.org/works/10.1002%2FIJC.23283

21 January 2018

Nuclear pore components are involved in the transcriptional regulation of dosage compensation in Drosophila

1 reference

https://api.crossref.org/works/10.1002%2FIJC.23283

21 January 2018

A human protein complex homologous to the Drosophila MSL complex is responsible for the majority of histone H4 acetylation at lysine 16

1 reference

https://api.crossref.org/works/10.1002%2FIJC.23283

21 January 2018

hMOF histone acetyltransferase is required for histone H4 lysine 16 acetylation in mammalian cells

1 reference

https://api.crossref.org/works/10.1002%2FIJC.23283

21 January 2018

Involvement of human MOF in ATM function

1 reference

https://api.crossref.org/works/10.1002%2FIJC.23283

21 January 2018

Acetylation of the p53 DNA-binding domain regulates apoptosis induction

1 reference

https://api.crossref.org/works/10.1002%2FIJC.23283

21 January 2018

Dose-dense primary systemic chemotherapy with gemcitabine plus epirubicin sequentially followed by docetaxel for early breast cancer: final results of a phase I/II trial

1 reference

https://api.crossref.org/works/10.1002%2FIJC.23283

21 January 2018

Expression of nuclear beta-catenin and c-myc is correlated with tumor size but not with proliferative activity of colorectal adenomas

1 reference

https://api.crossref.org/works/10.1002%2FIJC.23283

21 January 2018

A new mathematical model for relative quantification in real-time RT-PCR

1 reference

https://api.crossref.org/works/10.1002%2FIJC.23283

21 January 2018

Gene expression signature predicting pathologic complete response with gemcitabine, epirubicin, and docetaxel in primary breast cancer.

1 reference

https://api.crossref.org/works/10.1002%2FIJC.23283

21 January 2018

Genomic and protein expression profiling identifies CDK6 as novel independent prognostic marker in medulloblastoma

1 reference

https://api.crossref.org/works/10.1002%2FIJC.23283

21 January 2018

High-resolution genomic profiling reveals association of chromosomal aberrations on 1q and 16p with histologic and genetic subgroups of invasive breast cancer.

1 reference

https://api.crossref.org/works/10.1002%2FIJC.23283

21 January 2018

Stratification of medulloblastoma on the basis of histopathological grading.

1 reference

https://api.crossref.org/works/10.1002%2FIJC.23283

21 January 2018

Histone H4-K16 acetylation controls chromatin structure and protein interactions

1 reference

https://api.crossref.org/works/10.1002%2FIJC.23283

21 January 2018

Mutations truncating the EP300 acetylase in human cancers

1 reference

https://api.crossref.org/works/10.1002%2FIJC.23283

21 January 2018

Identifiers

10.1002/IJC.23283

1 reference

Europe PubMed Central

PubMed publication ID

26 December 2017

http://europepmc.org/abstract/MED/18058815

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

26 December 2017

http://europepmc.org/abstract/MED/18058815

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q46866555&oldid=2135316820"